Literature DB >> 3734254

Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements.

P Dorian, E S Fain, J M Davy, R A Winkle.   

Abstract

To investigate the influence of lidocaine on the energy requirements for internal defibrillation, lidocaine (n = 8) or saline solution (n = 12) was administered by intravenous infusion to 20 pentobarbital-anesthetized dogs, and the likelihood of successful defibrillation was examined at various shock energy levels before and after treatment. After lidocaine administration to a mean steady state concentration of 5.6 +/- 2.7 micrograms/ml, the mean energy required to achieve 50 and 90% success in defibrillation (E50 and E90) increased by 61.1 +/- 34.1% (mean +/- SD, p less than 0.005) and 47.1 +/- 28.6% (p less than 0.005), respectively. The steady state log lidocaine concentration correlated positively with the observed increase in E50 (r = 0.887, p less than 0.01) over a concentration range from 1.95 to 9.8 micrograms/ml. In a related experiment, lidocaine infusion was administered to five dogs and then abruptly discontinued. At energy levels achieving a mean 90.0 +/- 10.0% success in defibrillation before treatment, only 43.3 +/- 23.4% success was achieved after 60 minutes of the lidocaine infusion (p less than 0.01) at a mean plasma concentration of 8.4 +/- 2.1 micrograms/ml. The percent of successful defibrillations returned to baseline value (92.0 +/- 18.0%, p less than 0.01) after drug washout at a time when mean lidocaine concentration had declined to 1.8 +/- 0.5 microgram/ml. Lidocaine causes a reversible, concentration-dependent increase in the energy requirements for successful defibrillation; recommendations to administer lidocaine to patients with ventricular fibrillation resistant to defibrillation may need to be reviewed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734254     DOI: 10.1016/s0735-1097(86)80047-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.

Authors:  Yadavendra S Rajawat; Darryl Dias; Edward P Gerstenfeld; Sanjay Dixit; Bindi Shah; Andrea M Russo; Francis E Marchlinski
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 2.  Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.

Authors:  T J Campbell
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 3.  Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome.

Authors:  M Santini; C Pandozi; R Ricci
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

4.  Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.

Authors:  Peter J Kudenchuk; Siobhan P Brown; Mohamud Daya; Laurie J Morrison; Brian E Grunau; Tom Rea; Tom Aufderheide; Judy Powell; Brian Leroux; Christian Vaillancourt; Jonathan Larsen; Lynn Wittwer; M Riccardo Colella; Shannon W Stephens; Mark Gamber; Debra Egan; Paul Dorian
Journal:  Am Heart J       Date:  2014-03-01       Impact factor: 4.749

5.  The 1998 European Resuscitation Council guidelines for adult advanced life support. Advanced Life Support Working Group of the European Resuscitation Council.

Authors: 
Journal:  BMJ       Date:  1998-06-20

6.  Anti-arrhythmics in out-of-hospital cardiac arrest: lessons from a randomized controlled trial.

Authors:  Yann-Laurent Violin; Clément Derkenne; Daniel Jost; Jean-Pierre Tourtier
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 7.  Atrial Fibrillation in Patients with Congenital Heart Disease.

Authors:  Tabitha G Moe; Victor A Abrich; Edward K Rhee
Journal:  J Atr Fibrillation       Date:  2017-06-30

8.  Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.

Authors:  Zhongwei Cheng; Mintu Turakhia; Ronald Lo; Anurag Gupta; Paul C Zei; Henry H Hsia; Amin Al-Ahmad; Paul J Wang
Journal:  J Interv Card Electrophysiol       Date:  2012-03-06       Impact factor: 1.900

Review 9.  Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

10.  Effect of general anesthesia on the defibrillation energy requirement in patients undergoing defibrillator implantation.

Authors:  B P Knight; F Pelosi; M Flemming; F Morady; S A Strickberger
Journal:  J Interv Card Electrophysiol       Date:  1999-12       Impact factor: 1.900

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.